StreetInsider.com News Articles

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

MUMBAI, India and PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share updated results from the locally advanced cutaneous squamous cell carcinoma

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients

At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)

Tue, 26 May 2026 09:26:00 -0400

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event

Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients